In a study by Tang et al. [48], which evaluated the safety and efficacy of SGLT2 inhibitors in diabetic prostate cancer patients undergoing hormone therapy, the use of SGLT2 inhibitors was not associated with an increased risk of urinary tract infections, hypoglycemia, acute kidney injury, or diabetic ketoacidosis. This evidence concerns the gene SLC5A2 and prostate carcinoma.